Johnson & Johnson announced yesterday,Targeting EGFR MutationsFirst-line Treatment for Advanced StageClinical Trials of NSCLCMARIPOSA Study Meets Pre-Specified Secondary OS Endpoint，Amivantamab (Rybrevant) UnitedThe OS of Lazertinib (Lazcluze) compared to the control group OsimertinibImprovement with clinical significance and statistical significance. The predicted median OS improvement is expected to exceed one year.The combination of Amivantamab and Lazertinib was approved by the FDA last year for the treatment of NSCLC.At that time, early data based on Mariposa showed that this combination provided longer control of lung cancer compared to osimertinib. The trial involved nearly 1,100 untreated patients with locally advanced or metastatic NSCLC.The survival benefits of this combination therapy remain unclear. This release by Johnson & Johnson is also just a summary news item, stating that...The final results will not be released until the "upcoming medical conference."Osimertinib has become a best-selling anticancer drug because it is widely used to treat EGFR-mutated NSCLC. In the FLAURA study, osimertinib extended the median overall survival of patients to nearly 39 months.Mark Wildgust, Global Medical Affairs Leader for Oncology at Johnson & Johnson, said, "We expect the median overall survival time to be extended by more than a year."The survival benefit of Johnson & Johnson's program "may exceed four years" – surpassing previous studies.Osimertinib。Some analysts previously indicated that for patients who have not received treatment, doctors might prefer monotherapy over combination therapy, but better survival rates could make the latter more advantageous.Stephen Liu from Georgetown University School of Medicine stated that the survival benefits make Johnson & Johnson's treatment method more advantageous than other combination therapies.LiuHe served as a consultant to Johnson & Johnson and AstraZeneca, and predicted that patients who have received combination therapy will switch to Johnson & Johnson’s treatment regimen.On the other hand, inIn the MARIPOSA study, 10% acceptanceAmivantamab and LazertinibPatients discontinued treatment due to side effects, while only 3% of patients treated with osimertinib stopped treatment for the same reason. The Johnson & Johnson combination therapy was also associated with a type of blood clot formation in veins, prompting the FDA to require prophylactic anticoagulation therapy during the first few months of using the Johnson & Johnson treatment. Clinically, it is necessary to weigh the benefits against safety risks, and it is still difficult to say how much of an impact this combination will have on osimertinib.Welcome to follow and share! All articles in this official account can be freely reproduced as long as the source is acknowledged.
